INDUSTRY PARTICIPATION MANUAL

Terms And Conditions

KYOTO

Enter terms about covid compliance that we have considered.

VIrtual
Things you need to know

1.   The following are part of the contract between the exhibitor and/or sponsor and the congress managers, MCI Australia, and exhibitors/sponsors must observe these rules. In addition, any regulations imposed by the virtual platform must also be observed. Any areas not covered are subject to MCI’s final decision.

  • 1.1.   You (the sponsor/exhibitor) by returning a completed, signed and dated form explicitly accept these terms and conditions.
  • 1.2.   Details may change without notice. Please refer to the congress website for the latest information.
  • 1.3.   MCI Australia (ABN 76 108 781 988) representing the organising committee and the Host body does not accept responsibility for any errors, omissions or changes.
  • 1.4.   You agree that the organisers and other authorised stakeholders may use your contact information for any relevant purpose such as administration or advising of future events. You may ask us to limit communication to necessary matters.
  • 1.5.   The Platform and MCI do not take responsibility should internet connection become unstable. Internet connection is out of the control of MCI Australia and the Platform provider, it is the responsibility of the delegate/sponsor/stakeholder to have stable connection to access the platform.
  • 1.6.   We will use reasonable endeavours to provide constant, uninterrupted access to the Platform and the Services, but with any software product, this cannot be guaranteed. We will not be responsible or liable for any direct or indirect losses or damages suffered or sustained by you as a result of, or in connection with, any interruption or delay in accessing and using the Platform or the Services
Use of the platform

2.   You will not, and you will ensure the Authorised Users will not:

  • 2.1.   Modify the platform or merge any aspects of the platform with another programme other than as expressly provided under this Agreement.
  • 2.2.   Record, reverse engineer, copy, duplicate, reproduce, create derivate works from, frame, download, display, transmit or distribute any of the Platform, the source code of the Platform or any documents, manuals or setup instructions provided with the Platform or in relation to the Services
  • 2.3.   License, sell, rent, lease, transfer, assign or otherwise commercially exploit the Platform or the Services
  • 2.4.   Engage in unlawful behaviour, including unauthorised access to or use of data, services, systems or networks, including an attempt to probe, scan or test the vulnerability of a system or network or to break security or authentication measures
  • 2.5.   Access, store, distribute or transmit:
    • 2.5.1.   Viruses, work, trojan or other malicious code that corrupts, degrades or disrupts the operation of the Platform;
    • 2.5.2.   Material that is unlawful, unethical, harmful, threatening, defamatory, obscene, infringing, harassing or racially or ethnically offensive or a contravention of the rights of any third party;
    • 2.5.3.   Material that facilitates illegal activity, or
    • 2.5.4.   Material that abuses or causes damage or injury to any person or property
  • 2.6.   Provide Platform login details or password, or otherwise provide access to the Platform, to any unauthorised or unregistered third party and you will take all reasonable steps to prevent unauthorised access to, or use of, the Platform;
  • 2.7.   Share any features of the Platform that are not publicly available with any unauthorised third part; and
  • 2.8.   Engage in any conduct on the Platform that is in breach of this Agreement (or any agreements mentioned therein)
  • 2.9.   Any breach of this clause 1 constitutes a breach of this Agreement and we may, at our absolutely discretion, terminate or suspend your access to, and/or use of, the Platform or the Services, and/or take further actions against you for breach of this Agreement.
Services

3.   Services

  • 3.1.   All Services will be provided based on the information and specifications supplied by you. All information that we provide is supplied in good faith, but we do not warrant or guarantee the accuracy or completeness of any information provided by us or any third party. It is not within the scope of our obligations to enquire as to, or to verify, the accuracy of completeness of information that we receive from your or any third parties.
  • 3.2.   The Services, Deliverables and any Platform functionality specified in previous conversations are indicative only and may be amended by us from time to time. While we will use all reasonable endeavours to deliver the features and functionality specified therein, nothing in this Agreement prevents us from amending the Services at any time during the event delivery.
  • 3.3.   We will use reasonable endeavours to provide the Services promptly or by an applicable Delivery Date or such other dates as agreed by the parties in writing. Any Delivery Date or time quoted for delivery, commencement or completion of any part of the Services is an estimate only and time will not be of the essence.
Your obligations

4.   Your obligations

  • 4.1.   You acknowledge that our ability to be able to provide the Platform and the Services to you without delate or interruption is dependent on your full and timely cooperation. You will (and will ensure that the Authorised Users will)
    • 4.1.1.   Co-operate with and assist us in the supply of your Platform content;
    • 4.1.2.   Promptly provide us with full and accurate information, data and explanations as and when required;
    • 4.1.3.   Comply with applicable laws and regulations (including the General Data Protection regulation (“GDPR”) with respect to user privacy, data collection, data retention, data transmission, data storage and the use of cookies
    • 4.1.4.   Comply with all reasonable directions and guidelines from us as advised from time to time.
Financial facts

5.   We will have no liability for any losses suffered or any damage caused by errors or omissions in any information or instructions provided to us by you in connection with the Platform, the Services or any actions taken by as at your direction.

  • 5.1.   In no event will MCI Australia/APLAR be liable to you or any third party for any:
    • 5.1.1.   Loss of profits, revenue, goodwill or business, business interruption, corruption, loss or alteration of data, downtime costs, loss of use, failure to realise anticipated savings or for any indirect or consequential loss of damage of whatsoever nature, however caused;
    • 5.1.2.   Viruses worm, trojan or other malicious code introduced into, or transmitted to, your or any third part during the course of using the Platform or the Services;
You and your staff

6.   Your application to sponsor or exhibit does not constitute an attendee registration. You will need to do that separately as per the information provided in the manual.

  • 6.1.   Your staff (even if entitled to a complimentary registration) will be denied access to the event or exhibition unless they have completed the relevant registration form.
Exhibitor notes

7.   Exhibitor notes

  • 7.1.   You have a limited licence to exhibit. You may not assign, share, sub-let, or grant registrations for the whole or part of the booth without our prior approval.
  • 7.2.   We are the sole judge of acceptable display items and you will remove them promptly if asked.
  • You will be responsible for any reasonable costs should contents of your exhibition need to be changed, removed or updated.
  • 7.3.   You and your staff must be attired and behaved in accordance with the professional atmosphere of the event.
CSF blue logo transparent 300x300 (ACR+APLAR)

CSF

The Cytokine Signalling Forum (CSF) is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice. Visit our website at www.cytokinesignalling.com or follow us on social media at links below
Contact
Astellas logo

Sales Operation Area Management Support, Japan Commercial, Astellas Pharma Inc.

Janssen_300x300

Janssen, a division of Johnson & Johnson

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Lilly logo

Eli Lilly Japan K.K.

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Abbvie logo

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Bristol Myers Squibb logo

Bristol Myers Squibb K.K.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Gilead logo

Gilead Sciences K.K.

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple inflammatory conditions through a comprehensive clinical trial program evaluating novel agents with the goal of advancing patient care.

Novartis logo

Novartis Pharma K.K.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. We consistently rank among the world’s top companies investing in research and development.

Pfizer logo

Pfizer. Japan Inc

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Asahi Kasei Logo

Asahi Kasei Pharma Corporation

Asahi Kasei Pharma discovers, develops, manufactures, and delivers prescription drugs in the fields of orthopedics, circulatory, urology, the immune system, and the central nervous system.

Pharmaceuticals from Asahi Kasei Pharma include Teribone™ for osteoporosis and Elcitonin™ Injection 20S for osteoporosis pain, the Recomodulin™ anticoagulant, each of which has a competitive position in its respective market.

Kevzara® is a human monoclonal antibody that blocks the action of interleukin-6 (IL-6) by binding to IL-6 receptors, for the indication of rheumatoid arthritis in patients who have had an inadequate response to conventional treatments.

Kevzara® is a registered trademark of Sanofi Biotechnology.

The product information is intended for general information purposes. The names, descriptions, and labeling of approved products are of Japan origin.

Product availability, names, indications, and presentations may vary from country to country.

Boehringer Ingelheim logo

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of

19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: www.annualreport.boehringer-ingelheim.com.

Janssen logo

Janssen Pharmaceutical KK & Mitsubishi Tanabe Pharma Corporation

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Chugai logo

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.

Daiichi-Sankyo logo

Daiichi Sankyo Co., Ltd.

GSK Logo

Glaxosmithkline

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

UCB logo

UCB Biopharma SRL

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines. Our ambition is to transform the lives of people living with severe diseases, with a focus in immunology and neurology.

CSF Logo

Cesas Medical

The Cytokine Signalling Forum (CSF) is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.

AWR logo

Association of Women in Rheumatology

AWIR is a global organization with more than 11,000 touchpoints and 8 global chapters/partners worldwide. AWIR’s mission is to promote the science and practice of Rheumatology, foster the advancement and education of women in Rheumatology, and advocate access to the highest quality health care, and the management of patients with Rheumatic diseases.

LG Chem logo

LG Chem

LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area.

Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.

Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.

LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.

Contact
APLAR21-Placeholder (300x300)

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Contact